Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC)

Clinical Drug Investigation

Volumn 24, Issue 10, 2004, Pages 611-618

  Köster, Wolf ^a   Stamatis, G ^b   Heider, A ^c   Avramidis, K ^a   Wilke, H ^a   Koch, J A ^a   Stahl, M ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b RUHRLANDKLINIK   (Germany)

^c KLINIKUM LEVERKUSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CARBOPLATIN;

AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; DRUG HYPERSENSITIVITY; DRUG MIXTURE; DRUG TOLERANCE; FATIGUE; HEART ARRHYTHMIA; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL;

EID: 33747867253     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200424100-00007     Document Type: Article

References (14)

1. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20: 4618-20
2. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002; 29: 15-8
3. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. AntiCancer Drugs 2001; 12: 725-9
4. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002; 29: 27-32
5. Aivado M, Schulte K, Henze L, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29: 19-22
6. Pönisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol 2002; 29: 23-6
7. Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998; 124: 627-32
8. Reichmann U, Zeeb C, Huober J, et al. Salvage therapy for metastatic breast cancer: results of a phase II study with bendamustine [abstract]. Ann Oncol 2002; 13 Suppl. 5: 56
9. Schrijvers D, Vermorken JB. Phase I studies with bendamustine: an update. Semin Oncol 2002; 29: 15-8
10. Heider A, Köster W, Grote-Kiehn J, et al. Bendamustine in untreated small cell lung cancer (SCLC): efficacy and toxicity [abstract]. Eur J Cancer 1999; 35 Suppl. 4: 254
11. Köster W, Rudolph R, Stahl M. Bendamustine (Ribomustin®) chemotherapy in platinum pretreated small cell lung cancer patients (extensive disease) [abstract]. J Cancer Res Clin Oncol 2002; 128 Suppl. 1: P370
12. Reck M, Haering B, Koschel G, et al. Chemotherapie des fortgeschrittenen kleinzelligen und nichtkleinzelligen Bronchial-karzinoms mit Bendamustin. Eine Phase II Studie. Pneumologie 1998; 52: 571-4
13. Manegold C. Chemotherapie des kleinzelligen Bronchialkarzinoms. Der Onkologe 1998; 4: 1019-29
14. Schoffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000; 11 (6): 729-34